GO:0008611 ether lipid biosynthetic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008611 describes the biosynthesis of ether lipids, a class of glycerolipids in which a fatty alcohol is attached to glycerol via an ether bond, typically at the sn-1 position.
• Ether lipid biosynthesis is essential for membrane architecture, signaling, and cellular protection against oxidative stress, and is conserved from archaea to mammals.
• Key enzymes include glyceronephosphate O-acyltransferase (GNPAT), alkylglycerone phosphate synthase (AGPS), and fatty alcohol-forming enzymes such as FAR1 and FAR2.
• Dysregulation of ether lipid synthesis is linked to metabolic disorders, cancer, and peroxisomal diseases, making it a target for therapeutic and diagnostic research.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise interrogation of ether lipid biosynthetic genes in disease contexts.
• Studying this pathway requires integrated approaches such as lipidomics, transcriptomics, and flux analysis to capture its dynamic regulation.
Description
Ether lipids are a unique class of glycerolipids characterized by an ether linkage between a fatty alcohol and the glycerol backbone, most commonly at the sn-1 position. The biosynthetic process that generates these molecules, annotated as GO:0008611 (ether lipid biosynthetic process), encompasses the enzymatic steps that convert simple precursors into mature ether lipids, including plasmalogens. This pathway is evolutionarily ancient, with archaeal phospholipids relying on ether bonds for membrane stability under extreme conditions. In mammals, ether lipids are critical for membrane fluidity, signaling, and protection against oxidative stress, and their synthesis occurs primarily in peroxisomes. Research into ether lipid biosynthesis has gained momentum because of its implications in human health and disease. For example, peroxisomal alterations in prostate cancer are associated with metabolic shifts that involve ether lipid metabolism. In chronic kidney disease, macrophage lipid metabolism shows distinct alterations, including changes in ether lipid species. Additionally, sex differences in brown adipose tissue thermogenesis depend on PGC-1α-mediated phospholipid synthesis, which includes ether lipid components. These findings underscore the importance of understanding the molecular players and regulatory mechanisms of this pathway. This article provides a comprehensive overview of GO:0008611, covering its definition, biological significance, key genes, regulatory aspects, disease associations, and experimental methods. By integrating authoritative QuickGO data with verified PubMed literature, we aim to equip researchers with a resource for studying ether lipid biosynthesis in health and disease.
ether lipid biosynthetic process At A Glance
| GO ID | GO:0008611 |
|---|---|
| GO term | ether lipid biosynthetic process |
| Ontology | biological_process |
| Synonym | ether lipid anabolism; ether lipid biosynthesis; ether lipid formation; ether lipid synthesis; plasmalogen biosynthetic process |
| Major function | Synthesis of ether-linked glycerolipids, including plasmalogens, essential for membrane structure and signaling |
| Subcellular location | Peroxisomes (in eukaryotes) and archaeal membranes |
| Key enzymes | GNPAT, AGPS, FAR1, FAR2, and others |
| Related pathways | Lipid metabolism, peroxisomal disorders, oxidative stress response |
What Is GO:0008611?
GO:0008611, ether lipid biosynthetic process, is defined as the chemical reactions and pathways resulting in the formation of ether lipids, which are lipids containing one lipid alcohol in ether linkage to one of the carbon atoms (normally C-1) of glycerol. This process includes the synthesis of plasmalogens and other ether-linked glycerolipids, and it typically involves enzymes localized to peroxisomes in eukaryotes.
Why Is ether lipid biosynthetic process Important in Cell Biology?
Ether lipid biosynthesis is fundamental to cellular physiology because ether lipids, particularly plasmalogens, are major components of cell membranes and play critical roles in membrane dynamics, signaling, and antioxidant defense. Disruptions in this pathway are associated with a range of human diseases, including peroxisomal disorders, cancer, and metabolic syndromes. Understanding the regulation and function of ether lipid biosynthetic enzymes can reveal therapeutic targets and biomarkers for these conditions.
• Ether lipids are essential for membrane integrity and function, especially in the brain and heart.
• Plasmalogens, a major subclass of ether lipids, act as antioxidants and protect cells from oxidative stress.
• Defects in ether lipid synthesis cause peroxisomal disorders such as rhizomelic chondrodysplasia punctata.
• Altered ether lipid metabolism is observed in prostate cancer and may contribute to metabolic reprogramming.
• Chronic kidney disease induces changes in macrophage lipid metabolism, including ether lipid species.
• Brown adipose tissue thermogenesis relies on phospholipid synthesis, including ether lipids, and shows sex differences.
• Ether lipid biosynthesis is a potential target for modulating inflammation and metabolic diseases.
• Studying this pathway aids in understanding evolutionary adaptations in archaea and eukaryotes.
• CRISPR screening can identify novel regulators of ether lipid biosynthesis.
• Lipidomic profiling of ether lipids can serve as a diagnostic tool for related disorders.
What Happens During ether lipid biosynthetic process?
Initiation: Acylation of Dihydroxyacetone Phosphate
In simple terms: The pathway starts by attaching a fatty acid to a simple sugar-like molecule.
The first committed step in ether lipid biosynthesis is the acylation of dihydroxyacetone phosphate (DHAP) by glyceronephosphate O-acyltransferase (GNPAT) to form acyl-DHAP. This reaction occurs in peroxisomes and is essential for subsequent ether bond formation.
Ether Bond Formation: Action of AGPS
In simple terms: An enzyme swaps the fatty acid for a fatty alcohol, creating the characteristic ether bond.
Alkylglycerone phosphate synthase (AGPS) catalyzes the exchange of the acyl group in acyl-DHAP with a fatty alcohol, producing alkyl-DHAP. This step introduces the ether linkage and is a hallmark of ether lipid synthesis.
Reduction and Further Processing
In simple terms: The intermediate is converted into a more complex lipid that can be modified into different ether lipids.
Alkyl-DHAP is reduced to alkyl-glycerol-3-phosphate, which is then acylated and dephosphorylated to form alkylacylglycerol. This intermediate can be converted into plasmalogens or other ether lipids through the addition of polar head groups.
Fatty Alcohol Supply
In simple terms: The pathway needs a steady supply of fatty alcohols, which are made by specific enzymes.
Fatty alcohols used in ether bond formation are generated by fatty acyl-CoA reductases, such as FAR1 and FAR2. These enzymes reduce fatty acyl-CoAs to fatty alcohols, which are then utilized by AGPS.
Integration with Peroxisomal and ER Pathways
In simple terms: Ether lipid synthesis is split between different parts of the cell and connects to other lipid pathways.
Ether lipid biosynthesis begins in peroxisomes and continues in the endoplasmic reticulum, where final remodeling and head group addition occur. This compartmentalization allows integration with other lipid metabolic pathways and ensures proper membrane lipid composition.
Key Genes Involved in GO:0008611 ether lipid biosynthetic process
The following genes encode enzymes and regulators directly involved in ether lipid biosynthetic process, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GNPAT | Acylates DHAP to form acyl-DHAP, initiating ether lipid synthesis | Mutations cause rhizomelic chondrodysplasia punctata; target for peroxisomal disorder research |
| AGPS | Catalyzes ether bond formation by exchanging acyl for fatty alcohol | Key enzyme for plasmalogen synthesis; implicated in cancer metabolism |
| FAR1 | Reduces fatty acyl-CoAs to fatty alcohols for ether lipid synthesis | Regulates substrate supply; potential target for metabolic disorders |
| FAR2 | Fatty acyl-CoA reductase providing fatty alcohols | Overexpression studies link to lipid homeostasis |
| PEX7 | Peroxisomal targeting signal receptor for AGPS and GNPAT | Defects cause peroxisomal disorders affecting ether lipid synthesis |
| PEX5 | Peroxisomal import receptor for enzymes with PTS1 | Essential for peroxisomal enzyme import; mutations impair ether lipid synthesis |
| PGCla | Transcriptional coactivator regulating phospholipid synthesis genes | Sex-dependent role in BAT thermogenesis via phospholipid synthesis |
| FASN | Fatty acid synthase, provides acyl chains for lipid synthesis | Maintains lipid homeostasis in alveolar epithelial cells; linked to COPD |
| AMPK | Energy sensor regulating lipogenesis | Activation inhibits lipogenesis; studied in lipid accumulation models |
| PPARG | Nuclear receptor regulating lipid metabolism | Modulates expression of lipid synthesis genes |
| SREBP1 | Transcription factor controlling lipogenic gene expression | Regulates fatty acid and lipid synthesis pathways |
| ACOX1 | Peroxisomal acyl-CoA oxidase involved in fatty acid oxidation | Cross-talk with ether lipid synthesis in peroxisomes |
| CAT | Catalase, peroxisomal antioxidant enzyme | Protects against oxidative stress linked to ether lipid metabolism |
| ABCD1 | Peroxisomal transporter for very long-chain fatty acids | Mutations cause X-linked adrenoleukodystrophy with ether lipid abnormalities |
| HSD17B4 | Peroxisomal multifunctional enzyme | Defects affect peroxisomal lipid metabolism including ether lipids |
| ACAA1 | Peroxisomal thiolase | Involved in peroxisomal fatty acid oxidation; impacts lipid homeostasis |
How Is ether lipid biosynthetic process Regulated?
Ether lipid biosynthesis is regulated at multiple levels. Transcriptional control involves nuclear receptors such as PPARα and SREBP1, which modulate the expression of lipogenic genes. The energy sensor AMPK inhibits lipogenesis when activated, thereby affecting ether lipid synthesis. Additionally, PGC-1α coactivates transcription factors to promote phospholipid synthesis, including ether lipids, in a sex-dependent manner in brown adipose tissue. Peroxisomal biogenesis and import machinery, including PEX genes, are essential for the proper localization and function of ether lipid biosynthetic enzymes. Post-translational modifications and substrate availability further fine-tune the pathway.
ether lipid biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AGPS | Cancer (prostate), oxidative stress | Knockout in prostate cancer cell lines; lipidomic profiling |
| GNPAT | Rhizomelic chondrodysplasia punctata | Patient-derived fibroblasts; point mutation knock-in |
| FAR1 | Metabolic disorders, lipid homeostasis | Liver-specific knockout mice; overexpression in hepatocytes |
| PEX7 | Peroxisomal disorders | Knockout mice; CRISPR correction in patient cells |
| PGC-1α | Brown adipose tissue thermogenesis, sex differences | Adipose-specific knockout; knock-in of phospho-mimetic |
Ether Lipid Biosynthesis in Cancer
Alterations in ether lipid metabolism have been observed in prostate cancer, where peroxisomal changes contribute to metabolic shifts and clinical relevance. AGPS, a key enzyme in ether lipid synthesis, is upregulated in some cancers and supports cell survival under oxidative stress. Targeting ether lipid biosynthesis may therefore offer therapeutic opportunities in oncology.
Peroxisomal Disorders and Ether Lipid Deficiency
Defects in peroxisomal biogenesis or in enzymes such as GNPAT and AGPS lead to severe disorders like rhizomelic chondrodysplasia punctata, characterized by impaired plasmalogen synthesis. These conditions highlight the critical role of ether lipids in development and organ function.
Metabolic and Inflammatory Diseases
Chronic kidney disease induces distinct alterations in macrophage lipid metabolism, including ether lipid species, suggesting a role in inflammation and atherosclerosis. In obesity and diabetes, hypertriglyceridemia and altered lipid handling may intersect with ether lipid pathways. Furthermore, natural extracts that inhibit lipogenesis, such as Moringa oleifera leaf extract, modulate AMPK signaling and could affect ether lipid synthesis.
From ether lipid biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of AGPS impair ether lipid synthesis and cancer cell growth? | AGPS knockout in cancer cell lines (e.g., PC-3) |
| What is the effect of a specific point mutation in GNPAT on enzyme activity? | Point mutation knock-in in HEK293 cells |
| Can overexpression of FAR1 increase plasmalogen levels? | FAR1 overexpression in hepatocytes or mice |
| How does PGC-1α phosphorylation affect phospholipid synthesis? | Knock-in of phospho-mutant PGC-1α in brown adipocytes |
| Does macrophage ether lipid metabolism change in chronic kidney disease? | Macrophage-specific knockout in CKD mouse model |
| What is the role of AMPK in regulating ether lipid synthesis? | AMPK knockout or overexpression in lipid-accumulating cells |
How to Study the ether lipid biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics (LC-MS/MS) | Quantification of ether lipid species | Profiling plasmalogens in disease models |
| RNA-seq | Transcript levels of ether lipid genes | Identifying regulatory changes in cancer or metabolic disease |
| CRISPR knockout screening | Gene essentiality for ether lipid synthesis | Discovery of novel pathway regulators |
| Enzyme activity assay | Catalytic activity of GNPAT, AGPS, FARs | Validating point mutations or inhibitors |
| Western blot | Protein expression of ether lipid enzymes | Confirming knockout or overexpression |
| Immunofluorescence | Subcellular localization of enzymes | Assessing peroxisomal targeting |
| Flux analysis | Metabolic flux through ether lipid pathway | Measuring pathway activity in live cells |
| CRISPR interference (CRISPRi) | Knockdown of gene expression | Fine-tuning ether lipid gene dosage |
Lipidomics and Mass Spectrometry
Lipidomic profiling using mass spectrometry is the primary method to quantify ether lipid species, including plasmalogens. This approach can detect changes in response to genetic perturbations or disease states.
Transcriptomics and Gene Expression Analysis
RNA-seq and qPCR can measure the expression of genes involved in ether lipid biosynthesis, such as GNPAT, AGPS, and FAR1, providing insights into transcriptional regulation.
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout screens can identify novel regulators of ether lipid synthesis by selecting for cells with altered lipid profiles or survival under oxidative stress.
Enzyme Activity Assays
In vitro assays using recombinant enzymes or cell lysates can measure the catalytic activity of GNPAT, AGPS, and FARs, helping to validate functional variants.
How CRISPR Can Be Used to Study GO:0008611 ether lipid biosynthetic process
Knockout
CRISPR knockout of genes such as AGPS or GNPAT can completely abolish ether lipid synthesis, allowing researchers to study the consequences on membrane composition, cell survival, and disease phenotypes. Knockout models are essential for establishing causality.
Point Mutation
Introducing specific point mutations (e.g., in GNPAT or AGPS) via CRISPR can mimic patient-derived mutations, enabling structure-function studies and personalized disease modeling.
Knock-in
Knock-in of tagged versions of ether lipid enzymes (e.g., GFP-AGPS) allows real-time tracking of localization and dynamics. Knock-in of phospho-mimetic or phospho-deficient PGC-1α can dissect regulatory phosphorylation.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can increase levels of ether lipid enzymes like FAR1, leading to elevated plasmalogen synthesis and providing gain-of-function models for studying lipid homeostasis.
How EDITGENE Supports ether lipid biosynthetic process Research
Researchers studying ether lipid biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in pathway regulation, disease progression, or metabolic reprogramming. Precise genetic models are essential to move from correlation to causation.
Contact EDITGENE today to design your custom CRISPR model for ether lipid biosynthetic process research.
Frequently Asked Questions About ether lipid biosynthetic process
What is ether lipid biosynthetic process?
It is the biological process (GO:0008611) that produces ether lipids, which are glycerolipids with an ether bond at the sn-1 position, including plasmalogens.
What genes are involved in ether lipid biosynthetic process?
Key genes include GNPAT, AGPS, FAR1, FAR2, and peroxisomal import genes such as PEX7.
Where does ether lipid biosynthesis occur in the cell?
It begins in peroxisomes and continues in the endoplasmic reticulum.
What are plasmalogens?
Plasmalogens are a major subclass of ether lipids with a vinyl-ether bond, abundant in brain and heart, and act as antioxidants.
How is ether lipid biosynthesis regulated?
It is regulated transcriptionally by PPARα, SREBP1, and PGC-1α, and by energy sensors like AMPK.
What diseases are linked to ether lipid biosynthesis?
Peroxisomal disorders, cancer (e.g., prostate), chronic kidney disease, and metabolic syndromes.
How can CRISPR be used to study ether lipid biosynthesis?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of pathway genes to study function and disease.
What methods measure ether lipid levels?
Lipidomics using mass spectrometry is the gold standard, complemented by transcriptomics and enzyme assays.
Is ether lipid biosynthesis conserved in archaea?
Yes, archaeal phospholipids rely on ether bonds, and the biosynthetic machinery shares similarities with eukaryotic pathways.
What is the role of AGPS in cancer?
AGPS is often upregulated in cancer and supports cell survival under oxidative stress, making it a potential therapeutic target.
Conclusion
Ether lipid biosynthetic process (GO:0008611) is a fundamental metabolic pathway with critical roles in membrane biology, antioxidant defense, and human disease. The integration of QuickGO annotations with verified literature highlights key enzymes, regulatory mechanisms, and disease associations. Advances in CRISPR-based models and lipidomics will continue to unravel the complexities of this pathway, offering new opportunities for therapeutic intervention.
References
- 1. Caforio A et al.. 2017. Archaeal phospholipids: Structural properties and biosynthesis.. Biochim Biophys Acta Mol Cell Biol Lipids 1862(11):1325-1339 PMID: 28007654
- 2. Fan LC et al.. 2023. Alveolar type II epithelial cell FASN maintains lipid homeostasis in experimental COPD.. JCI Insight 8(16) PMID: 37606038
- 3. Takeuchi A et al.. 2025. Sex difference in BAT thermogenesis depends on PGC-1α-mediated phospholipid synthesis in mice.. Nat Commun 16(1):6072 PMID: 40659621
- 4. Saum K et al.. 2026. Chronic kidney disease induces distinct alterations of macrophage lipid metabolism in a mouse model of atherosclerosis.. J Lipid Res 67(2):100975 PMID: 41485713
- 5. Wang H et al.. 2024. Curcuma wenyujin rhizomes extract ameliorates lipid accumulation.. Fitoterapia 175:105957 PMID: 38604260
- 6. Xie J et al.. 2018. Moringa oleifera Leaf Petroleum Ether Extract Inhibits Lipogenesis by Activating the AMPK Signaling Pathway.. Front Pharmacol 9:1447 PMID: 30618744
- 7. Subramanian S et al.. 2012. Hypertriglyceridemia secondary to obesity and diabetes.. Biochim Biophys Acta 1821(5):819-25 PMID: 22005032
- 8. Hussein MAF et al.. 2025. Peroxisomal Alterations in Prostate Cancer: Metabolic Shifts and Clinical Relevance.. Cancers (Basel) 17(13) PMID: 40647540
